The Impact of Known XXXX on Long-Term Outcomes of Catheter Ablation in @entity1 with Atrial Fibrillation and Left Ventricular Systolic Dysfunction: A Multicenter International Study.

@entity1 @entity296 @entity2033 @entity1000 @entity299
BACKGROUND: Catheter ablation for AF is an effective treatment for @entity1 with AF and systolic LV dysfunction; however, the clinical outcome is variable. We evaluated the impact of @entity296 etiology on long-term outcomes post-catheter ablation. METHODS: @entity1 undergoing AF ablation across 3 centers (2 Australian, 1 UK) from 2002 to 2014, with LVEF<45% were evaluated. @entity1 were stratified into those with known @entity299 as a cause of @entity296 (KHD), and those with @entity1000 ( @entity1000 ). RESULTS: One hundred and one @entity1 ( @entity1000 = 77, KHD = 24) with AF and LVEF <45% underwent AF ablation. The KHD group (ischemic @entity2033 in 67%) were older (61    7 vs. 55    11 years, P = 0.005), with a higher CHADS2 score (2.0    0.8 vs. 1.6    0.7, P = 0.016), but otherwise well matched. After mean follow-up of 36    23 months, AF control was greater in the @entity1000 group (82% vs. 50% in KHD, P < 0.001). On multivariate analysis @entity1000 was associated with long-term AF control (P = 0.033). The @entity1000 group had less functional impairment at follow-up (NYHA class 1.5    0.7 vs. 2.0    0.8, P = 0.005) and improved LVEF (50    11% vs. 38    10%, P < 0.001). Super responders (EF improvement >15%) were overwhelmingly in the @entity1000 group (94% vs. 6%, P < 0.001) with greater AF control (89% vs. 61%, P < 0.001). All-cause mortality was significantly higher in the KHD group (17% vs. 1.3%, P = 0.002). CONCLUSION: @entity1000 was associated with greater AF control, and improvement in symptoms and LVEF compared to @entity1 with KHD post-AF ablation. AF is an important reversible cause of HF in @entity1 with an unexplained CM and catheter ablation an effective treatment option.
